Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
2. Blaston
3. Cinitapride
4. Cinitapride Tartrate
1. Cinitapride Hydrogen Tartrate
2. 67135-13-1
3. Las 17177
4. 4-amino-n-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide;(e)-but-2-enedioic Acid
5. Benzamide, 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidinyl)-2-ethoxy-5-nitro-, (e)-2-butenedioate (1:1)
Molecular Weight | 518.6 g/mol |
---|---|
Molecular Formula | C25H34N4O8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 8 |
Exact Mass | 518.23766406 g/mol |
Monoisotopic Mass | 518.23766406 g/mol |
Topological Polar Surface Area | 188 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 705 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Cinitapride Hydrogen Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cinitapride Hydrogen Tartrate, including repackagers and relabelers. The FDA regulates Cinitapride Hydrogen Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cinitapride Hydrogen Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cinitapride Hydrogen Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cinitapride Hydrogen Tartrate supplier is an individual or a company that provides Cinitapride Hydrogen Tartrate active pharmaceutical ingredient (API) or Cinitapride Hydrogen Tartrate finished formulations upon request. The Cinitapride Hydrogen Tartrate suppliers may include Cinitapride Hydrogen Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Cinitapride Hydrogen Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cinitapride Hydrogen Tartrate written confirmation (Cinitapride Hydrogen Tartrate WC) is an official document issued by a regulatory agency to a Cinitapride Hydrogen Tartrate manufacturer, verifying that the manufacturing facility of a Cinitapride Hydrogen Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cinitapride Hydrogen Tartrate APIs or Cinitapride Hydrogen Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cinitapride Hydrogen Tartrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Cinitapride Hydrogen Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.
Cinitapride Hydrogen Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cinitapride Hydrogen Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cinitapride Hydrogen Tartrate GMP manufacturer or Cinitapride Hydrogen Tartrate GMP API supplier for your needs.
A Cinitapride Hydrogen Tartrate CoA (Certificate of Analysis) is a formal document that attests to Cinitapride Hydrogen Tartrate's compliance with Cinitapride Hydrogen Tartrate specifications and serves as a tool for batch-level quality control.
Cinitapride Hydrogen Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Cinitapride Hydrogen Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cinitapride Hydrogen Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cinitapride Hydrogen Tartrate EP), Cinitapride Hydrogen Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cinitapride Hydrogen Tartrate USP).
LOOKING FOR A SUPPLIER?